Applying the results of large clinical trials in the management of acute myocardial infarction.
Mortality from acute myocardial infarction has declined in recent years, largely due to the widespread application of new pharmacologic and mechanical interventions that have been tested in large, prospective, randomized clinical trials. For practicing generalists, we review the key data from such trials that have shaped the current management of patients with acute myocardial infarction. We discuss the roles of thrombolytic therapy, coronary angioplasty, nitrates, beta- and calcium channel blockers, angiotensin-converting-enzyme inhibitors, magnesium, and antiarrhythmic and antithrombotic agents. In addition, we highlight critical unanswered questions in the management of this disorder.
Sweeney
J P
JP
Cardiology Section, Department of Veterans Affairs (VA) Medical Center, San Francisco, CA 94121, USA.
Schwartz
G G
GG
D015906:Angioplasty, Balloon, Coronary; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000601:surgery; D018579:Patient Selection; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants